Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
MALVERN, Pa., April 04, 2016 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at Needham & Company’s 15th Annual Healthcare Conference, on Wednesday, April 13, at 3 p.m. EDT at the Westin New York Grand Central Hotel in New York City.
For additional information on the conference, please visit: http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx.
About PhaseBio
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel drugs to treat metabolic and specialty cardiopulmonary disorders. The Company's proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects. PhaseBio's lead development candidates include: PE0139, a novel, super-long-acting basal insulin-ELP fusion for once-weekly dosing; and PB1046, a weekly vasoactive intestinal peptide receptor agonist for the treatment of acute and chronic heart failure, the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, Becker muscular dystrophy and X-linked dilated cardiomyopathy, and other indications. PhaseBio is privately owned with headquarters and research laboratories in Malvern, Pa.
Media Contact: Laura Bagby, 6 Degrees (312) 448-8098 [email protected]
